browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
8c8d53c3-5877-4567-869e-bac49b26a3a6
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 19:14:17
Income (reported)
Expenses (reported)
$1,320,000
Expenses method
A
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

BRISTOL-MYERS SQUIBB COMPANY

Lobbying on biopharmaceutical issues.

Contact
LAURA DAVIS EIDSON
Phone
+1 727-519-5721
Address
zip:20004, city:WASHINGTON, state:DC, street:801 Pennsylvania Ave, NW, Suite 745
Client

BRISTOL-MYERS SQUIBB COMPANY

State
DC
Country
US
Government-entity client
false
Effective date
2013-05-21
Issues lobbied + lobbyists (5)

HCR — Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TAX — Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.